Back to Journals » Patient Preference and Adherence » Volume 12

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

Authors Kosmas CE, Silverio D, Ovalle J, Montan PD, Guzman E

Received 31 August 2018

Accepted for publication 5 October 2018

Published 29 October 2018 Volume 2018:12 Pages 2263—2266


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen

Constantine E Kosmas,1 Delia Silverio,2 Julio Ovalle,2 Peter D Montan,2 Eliscer Guzman3

1Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, NY, USA; 2Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA; 3Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA

Abstract: Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at home appears to be safe and effective with the appropriate training and instructions from a health care provider. Current studies are showing encouraging results regarding adherence to evolocumab in real-life settings, and adherence rates to evolocumab appear to be better than those to statins. However, further larger studies are needed for a more definitive assessment of the short- and long-term patient adherence rates to evolocumab. In addition, reductions in the price of evolocumab may also be necessary to improve cost-effectiveness of the drug.

Keywords: evolocumab, adherence, hypercholesterolemia, cardiovascular risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]